Home › Therapeutic areas › Oncology › Myelodysplastic Syndrome
Myelodysplastic Syndrome (4 companies)
Companies with an active program in Myelodysplastic Syndrome.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| GERN | Geron | Oncology | 1 | Approved | $638M | 3 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $184M | 5 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.8M | 4 |
No companies match.